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Abstract
Compared to the association between cigarette smoking and psychiatric disorders,
relatively little is known about the relationship between smokeless tobacco use and
psychiatric disorders. To identify the psychiatric correlates of smokeless tobacco
use, the analysis used a national representative sample from the National
Epidemiologic Survey on Alcohol and Related Conditions (NESARC) wave 1.
Smokeless tobacco use was classified as exclusive snuff use, exclusive chewing
tobacco, and dual use of both snuff and chewing tobacco at some time in the
smokeless tobacco user’s life. Lifetime psychiatric disorders were obtained via
structured diagnostic interviews. The results show that the prevalence of lifetime
exclusive snuff use, exclusive chewing tobacco, and dual use of both snuff and
chewing tobacco was 2.16%, 2.52%, and 2.79%, respectively. After controlling for
sociodemographic variables and cigarette smoking, the odds of exclusive chewing
tobacco in persons with panic disorder and specific phobia were 1.53 and 1.41
times the odds in persons without those disorders, respectively. The odds of
exclusive snuff use, exclusive chewing tobacco, and dual use of both products for
individuals with alcohol use disorder were 1.97, 2.01, and 2.99 times the odds for
those without alcohol use disorder, respectively. Respondents with cannabis use
disorder were 1.44 times more likely to use snuff exclusively than those without
cannabis use disorder. Respondents with inhalant/solvent use disorder were
associated with 3.33 times the odds of exclusive chewing tobacco. In conclusion,
this study highlights the specific links of anxiety disorder, alcohol, cannabis, and
inhalant/solvent use disorders with different types of smokeless tobacco use.
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Introduction
The use of smokeless tobacco is a significant yet understudied public health
problem. According to the national health surveys, smokeless tobacco use among
U.S. adults ranged from 0.8% to 9.2% [1, 2]. Smokeless tobacco products are a
major source of carcinogenic nitrosamines and associated with increased risk for
oral, esophageal, and pancreatic cancer [3–5]. The International Agency for
Research on Cancer has classified smokeless tobacco as a human carcinogen [6].
In addition, smokeless tobacco use increases myocardial infarction and stroke [7].
In North America and parts of Europe, the most commonly used smokeless
tobacco products include snuff (dry or moist) or (and?) chewing tobacco. Moist
snuff is the most popular smokeless tobacco product used in the United States [8].
Smokeless tobacco is most commonly used by younger Caucasian men, some
Native American and Alaska Native tribes, and residents of rural areas [8].
Smokeless tobacco use has been linked to elevated risk for alcohol, cigarette, and
marijuana use along with depression in the National Institute on Drug Abuse
National Household Survey [9]. The findings on the association between
smokeless tobacco use and psychiatric disorders are mixed in the current
literature. Previous studies have indicated that past-year smokeless tobacco users
who met lifetime DSM-IV diagnostic criteria for nicotine dependence were
associated with increased risk for specific phobia after controlling for
demographic and psychiatric covariates as well as quantity of cigarettes smoked
[10]. In contrast, past-year smokeless tobacco users without nicotine dependence
were not associated with any psychiatric disorders [10]. These results were
obtained based on the smokeless tobacco users who had used any smokeless
tobacco products in the past 12 months prior to the interview and did not show
whether both snuff and chewing tobacco were associated with specific phobia.
Another report found that there was no association between exclusive smokeless
tobacco use and cannabis use disorder, but the dual use of smoked and smokeless
tobacco was (were?) associated with greater odds of cannabis use disorder [11].
Most previous studies did not measure psychiatric disorders [3–5], or restricted
study inclusion to past year smokeless tobacco use rather than lifetime use
[10, 11]. Thus, some lifetime smokeless tobacco users were misclassified as non-
users, potentially missing important relations. Previous studies also did not
differentiate any specific form of smokeless tobacco when relations of smokeless
tobacco use with psychiatric disorders were examined [10, 11]. As a result, it is
unknown whether psychiatric comorbidities are similar in solely snuff users, solely
chewing tobacco users, or dual users. It is also unknown whether findings from
past-year smokeless tobacco users can be generalized to lifetime users.
To address these gaps in smokeless tobacco research, the present study utilizes a
large, nationally representative sample to clarify some ongoing issues in the study
of lifetime smokeless tobacco use and lifetime psychiatric disorders. This study
examined differences between lifetime smokeless tobacco users and non-users of
smokeless tobacco in relation to psychiatric disorders. Moreover, this study
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delineated exclusive snuff use or exclusive chewing tobacco from dual use with
respect to psychiatric disorders.
Materials and Methods
Sample
Data was derived from the National Epidemiologic Survey of Alcohol and Related
Conditions (NESARC) wave 1 sponsored by the National Institute on Alcohol
Abuse and Alcoholism (NIAAA) and conducted by the U.S. Bureau of the Census
in 2001 and 2002. A sample of 43,093 non-institutionalized civilians 18 years and
older was selected from the U.S. population. The person-to-person interview
survey oversampled young adults, Hispanics, and African-Americans. The overall
response rate was 81%. The sample was weighted and adjusted to reflect the U.S.
population from the 2000 Decennial Census with respect to age, sex, race and
ethnicity to account for non-response and selection probability. Details of the
sampling frame and weighting method are published elsewhere [12–15]. All
respondents provided a written informed consent to participate in the NESARC.
The research protocol and informed consent procedures were reviewed and
approved by the U.S. Bureau of the Census and the U.S. Office of Management
and Budget.
Measures
Psychiatric diagnoses were made using the Alcohol Use Disorder and Associated
Disabilities Interview Schedule-IV (AUDADIS-IV), a computer- assisted interview
software developed by the NIAAA,according to the Diagnostic and Statistical
Manual of Mental Disorders IV (DSM-IV) [16]. Experienced professional
interviewers from the U.S. Bureau of the Census were trained under the direction
of NIAAA. A subsample was randomly selected and re-interviewed with one to
three complete sections for the purpose of quality control and rest-retest reliability
analysis [17]. These results indicated that the AUDADIS_IV possessed good
reliability and validity [18–22].
Smokeless tobacco use
Lifetime smokeless tobacco users were defined if they answered affirmatively to
the question in the NESARC, ‘‘In your entire life, have you ever used snuff, such
as Skoal, Skoal Bandit or Copenhagen at least 20 times?’’ or ‘‘In your entire life,
have you ever used chewing tobacco, such as Redman, Levi Garrett or Beechnut at
least 20 times?’’. Lifetime cigarette users were defined if they answered
affirmatively to the question, ‘‘In your entire life, have you ever smoked at least
100 cigarettes?’’ The quantity of cigarettes was obtained according to the question,
‘‘Thinking back over the entire period when you were smoking every day, about
how many cigarettes did you usually smoke in a single day?’’
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Sociodemographic covariates
Sociodemographic variables included age, sex, race/ethnicity, marital status,
household income, educational attainment, metropolitan area, regions, and birth
in the United States. Age was divided into the categories 18–34, 35–49, 50–64, and
65+. Race/ethnicity was classified into White, African-American, Hispanic, and
American Indian/Alaska Native/Asian/Native Hawaiian/Pacific Island. Marital
status was classified as never married, married, and widowed/separated/divorced.
Household income was categorized as ,$20,000, $20,000–$34,999, $35,000–
$69,999, and $$70,000. Educational attainment was classified as less than high
school, high school graduates, and college or higher education.Psychiatric
diagnosis.
Lifetime DSM-IV psychiatric diagnoses included major depression, dysthymia,
mania or hypomania, panic disorder, social phobia, specific phobia, general
anxiety disorder, alcohol use disorder, nicotine dependence, cannabis use
disorder, cocaine use disorder, sedatives use disorder, hallucinogens use disorder,
opiates use disorder, tranquilizers use disorder, inhalants use disorder, antisocial
personality disorder, avoidant personality disorder, dependent personality
disorder, histrionic personality disorder, paranoid personality disorder, schizoid
personality disorder, and obsessive-compulsive personality disorder. The test-
retest reliability has been documented for mood and anxiety disorder diagnoses
and symptom items (kappas 0.42–0.64) [17] for the alcohol dependence diagnosis
(kappas 0.7–0.84) [17–20] and nicotine dependence diagnosis (kappa 50.63)
[12, 14] [1, 2] respectively. Good validity of psychiatric diagnoses has also been
documented elsewhere [21, 22].
Statistical Analysis
All analyses were conducted using SUDAAN [23]. This software implements a
Taylor series linearization to adjust standard errors of estimates for complex
survey sampling design effects including clustered data. The dependent variable of
smokeless tobacco use was recoded as exclusive snuff use, exclusive chewing
tobacco, use of both snuff and chewing tobacco, and non-tobacco use (reference
group). Based on the number of cigarettes smoked per day, an ordinal variable
was recoded as 0, 1–5, 6–15, 16–29, 30+. Weighted percentages were used to
report the prevalence of sociodemographic characteristics and psychiatric
disorders by smokeless tobacco use status. Since a chi-square test is not very
informative for contingency tables beyond 262 dimensions, we conducted a
significance test using 95% confidence interval (CI) of prevalence. 95% CIs of two
prevalence estimates not overlapping indicates p,0.05. We used multinomial
logistic regression to detect associations between lifetime smokeless tobacco use
and psychiatric disorders while controlling for sociodemographic covariates and
quantity of cigarettes smoked. Adjusted odds ratios (OR) and 95% CI were
reported to quantify the associations.
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Table 1. Sociodemographic characteristics of respondents stratified by non-smokeless tobacco use, exclusive snuff use, exclusive chewing tobacco, and
dual use of snuff and chewing tobacco.
Non-smokeless
tobacco
use(n523,442) Snuff(n5716)
Chewing
tobacco(n5901)
Snuff and chewing
tobacco(n5931)
% (95%CI) % (95%CI) % (95%CI) % (95%CI)
Sex
Male 44.13 (43.47, 44.80) 91.16 (88.76–93.09) 94.39 (92.67–95.72) 95.89 (94.30–97.05)
Female 55.87 (55.20, 56.53) 8.84 (6.91–11.24) 5.61 (4.28–7.33) 4.11 (2.95–5.70)
Age
18–34 31.08 (30.18, 32.00) 47.98 (43.41–52.59) 23.12 (19.98–26.60) 40.46 (36.75–44.29)
35–49 30.93 (30.30, 31.56) 33.36 (29.36–37.61) 30.43 (26.79–34.33) 36.20 (32.53–40.03)
50–64 21.41 (20.88, 21.95) 12.15 (9.78–15.01) 24.50 (21.22–28.10) 14.67 (12.24–17.49)
65+ 16.58 (15.88, 17.30) 6.51 (5.03–8.39) 21.95 (19.14–25.05) 8.68 (6.89–10.87)
Race
Black 11.53 (10.26, 12.93) 3.26 (2.33–4.54) 8.17 (6.53–10.19) 4.02 (3.05–5.27)
Hispanic 12.13 (9.79, 14.94) 4.33 (2.89–6.50) 3.61 (2.19–5.90) 4.11 (2.73–6.14)
Indian/Alaska/Asian/Hawaiian-Pacific 6.65 (5.65, 7.81) 4.36 (2.89–6.53) 4.45 (3.17–6.21) 4.85 (3.35–6.97)
White 69.69 (66.32, 72.86) 88.05 (85.33–90.33) 83.77 (80.84–86.33) 87.02 (84.27–89.36)
Income
,$19,999 23.88 (22.92, 24.87) 16.95 (13.96–20.43) 23.37 (19.78–27.40) 19.26 (16.54–22.29)
$20,000–$34,999 20.00 (19.33, 20.68) 21.53 (18.16–25.32) 20.55 (17.53–24.32) 21.84 (19.11–24.84)
$35,999–$69,999 31.82 (31.17, 34.47) 38.64 (34.53–42.92) 35.49 (31.54–39.64) 35.42 (31.97–39.02)
.$69,999 24.30 (22.90, 25.76) 22.88 (19.38–26.81) 20.59 (17.20–24.45) 22.88 (19.38–26.81)
Marital Status
Never married 20.84 (19.89, 21.83) 23.43 (19.50–27.88) 14.36 (11.50–17.79) 20.50 (17.49–23.87)
Separated/divorced/widowed 17.70 (17.21, 18.20) 14.06 (11.63–16.91) 15.85 (13.58–18.41) 13.90 (11.55–16.64)
Married/Cohabitating 61.46 (60.51, 62.40) 62.51 (57.97–66.84) 69.79 (66.19–73.16) 65.61 (61.72–69.29)
Education
,High school 15.42 (14.43, 16.47) 15.62 (12.74–19.01) 22.11 (19.04–25.51) 16.72 (14.02–19.82)
High school graduates 28.87 (27.77, 30.00) 33.99 (29.74–38.51) 34.45 (31.00–38.08) 33.95 (30.33–37.77)
College or higher 55.71 (54.41, 56.99) 50.39 (46.07–54.70) 43.44 (39.66–47.31) 49.33 (45.20–53.46)
Urbanicity
Central city 30.19 (25.88, 34.89) 19.21 (15.55–23.49) 20.87 (17.51–24.67) 20.93 (17.59–24.71)
Suburban or rural 69.81 (65.11, 74.12) 80.79 (76.51–84.45) 79.31 (75.33–82.49) 79.07 (75.29–82.41)
Regions
Northeast 20.14 (13.99, 28.11) 15.81 (10.49–23.13) 13.70 (9.38–19.60) 11.24 (7.93–15.69)
Midwest 23.02 (17.09, 30.25) 26.00 (20.76–32.02) 22.45 (17.47–28.35) 26.78 (21.81–32.40)
South 34.60 (28.30, 41.50) 36.60 (30.30–43.40) 47.23 (40.84–53.72) 42.99 (36.91–49.30)
West 22.24 (15.84, 30.30) 21.59 (16.61–27.58) 16.62 (11.94–22.66) 18.99 (14.03–25.19)
Born in US
Yes 84.40 (81.05, 87.25) 97.98 (95.18–99.17) 97.16 (95.33–98.28) 98.01 (96.87–98.86)
No 15.60 (12.75, 18.95) 2.02 (0.83–4.82) 2.84 (1.72–4.67) 1.90 (1.14–3.13)
Cigarettes Smoked
Yes 41.74 (40.43.03) 70.12 (66.24, 73.72) 75.17 (71.66, 78.37) 74.37 (71.05, 77.44)
No 58.26 (56.97, 59.54) 29.88 (26.28, 33.76) 24.83 (21.63, 28.34) 25.63 (22.56, 28.95)
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Results
Table 1 displays the sociodemographic characteristics of respondents stratified by
a history of smokeless tobacco use at some point in their life. Smokeless tobacco
use was significantly more common in Caucasians, men, people aged 18 to 34
years old, those born in the United States, and residents of suburban and rural
areas. Smokeless tobacco use was less common among African Americans and
Hispanics. Exclusive chewing tobacco and use of both snuff and chewing tobacco
were less likely to report in persons aged 50 years or older compared to non-
smokeless tobacco use. Exclusive chewing tobacco was more common in people
who were married, but less common in those who were never married compared
to non-smokeless tobacco use. Those who were divorced, separated, widowed, or
came from families with household incomes less than $20,000 were less likely to
use only snuff or both snuff and chewing tobacco. There was no difference in
prevalence between smokeless tobacco use and non-smokeless tobacco use among
people with household incomes greater than $70,000. Persons who did not
complete their high school education were more likely to chew tobacco only. High
school graduates were more likely to use any smokeless tobacco products, but
individuals with college or higher education were less likely to use both snuff and
chewing tobacco or only chew tobacco.
Table 2 shows the lifetime prevalence of psychiatric disorders and smoking
among respondents divided by their history of smokeless tobacco use at some
point in their life. Mania/hypomania was more likely to be associated with
exclusive snuff use and use of both snuff and chewing tobacco. Obsessive-
compulsive, paranoid, Schizoid, and histrionic personality disorders were more
likely to be associated with use of both snuff and chewing tobacco. Antisocial
personality disorder, and substance user disorders including alcohol, cannabis,
amphetamine, opiates, sedatives, cocaine, and hallucinogens were significantly
associated with all types of smokeless tobacco use compared to non-smokeless
tobacco use. Tranquilizer, heroin and inhalant use disorders were significantly
associated with exclusive chewing tobacco and dual use of snuff and chewing
tobacco. Cigarette smoking was more likely to be associated with any types of
smokeless tobacco use.
Table 3 presents associations between lifetime smokeless tobacco use and
lifetime DSM-IV diagnoses of psychiatric disorders after controlling for socio-
demographic covariates and cigarette smoking using a multinomial logit model.
The adjusted odds of chewing tobacco in people with panic disorder and specific
phobia were 1.53 and 1.41 times theodds in people without panic disorder and
specific phobia, respectively. Alcohol use disorder was associated with 1.97, 2.01,
and 2.99 times the odds of using snuff only, chewing tobacco only, and dual use of
both tobacco products, respectively. Cannabis use disorder was associated with
1.44 times the odds of exclusive snuff use compared to non-cannabis use disorder.
Note: Boldface percentages are significantly different from those in the non-smokeless tobacco use group (p,0.05).
doi:10.1371/journal.pone.0113196.t001
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Opioid use disorder was associated with 1.81 times the odds of dual use of snuff
and chewing tobacco. Inhalant and solvent use disorder was associated with 3.33
times the odds of exclusive chewing tobacco compared to non-inhalant/solvent
use disorder.
Table 2. Prevalence of lifetime psychiatric disorders and cigarette smoking among respondents stratified by lifetime use of smokeless tobacco.
Non-smokeless tobacco
use(n523,442) Snuff(n5716)
Chewing
tobacco(n5901)
Snuff and chewing
tobacco(n5931)
% (95%CI) % (95%CI) % (95%CI) % (95%CI)
Mood disorders
Major depression 16.73 (15.93, 17.50) 16.74 (13.76–20.22) 13.48 (11.25–16.07) 18.80 (16.04–21.92)
Dysthymia 4.31 (4.02, 4.62) 4.00 (2.37–6.68) 4.86 (3.62–6.50) 5.36 (3.85–7.42)
Mania/hypomania 5.46 (5.12, 5.83) 8.85 (6.44–12.06) 7.31 (5.55–9.57) 9.25 (7.45–11.42)
Anxiety disorders
Panic disorder 4.05 (3.78, 4.33) 3.33 (1.96–5.60) 5.35 (3.74–7.61) 3.14 (1.97–4.98)
Social phobia 4.96 (4.57, 5.38) 6.74 (4.66–9.65) 6.00 (4.22–8.47) 4.87 (3.46–6.81)
Specific phobia 9.48 (8.88, 10.12) 9.38 (6.96–12.54) 10.68 (8.44–13.44) 8.52 (6.49–11.11)
General Anxiety Disorder 4.20 (3.86, 4.56) 3.84 (2.55–5.74) 3.20 (2.21–4.59) 4.77 (2.99–7.54)
Personality Disorder
Avoidant 2.32 (2.11, 2.56) 3.08 (1.78–5.26) 2.58 (1.53–4.31) 3.36 (1.94–5.77)
Dependent 0.48 (0.40, 0.58) 0.45 (0.12–1.76) 0.49 (0.17–1.41) 1.10 (0.42–2.86)
Obsessive-Compulsive 7.70 (7.26, 8.18) 10.37 (7.70–13.83) 9.90 (7.84–12.44) 12.62 (10.23–15.47)
Paranoid 4.32 (4.02, 4.64) 6.32 (4.29–9.21) 4.87 (3.45–6.83) 7.15 (5.17–9.81)
Schizophrenic 3.07 (2.83, 3.34) 2.85 (1.71–4.70) 3.84 (2.44–5.99) 5.69 (4.05–7.92)
Antisocial 3.16 (2.89, 3.44) 10.95 (8.19–14.49) 6.90 (5.14–9.14) 11.92 (9.57–14.75)
Histrionic 1.76 (1.61, 1.92) 2.09 (1.21–3.60) 2.92 (1.78–4.74) 3.88 (2.62–5.72)
Conduct disorder 1.05 (0.92, 1.20) 1.23 (0.56–2.68) 0.94 (0.46–1.89) 1.59 (0.91–2.77)
Substance Use Disorders
Alcohol 27.52 (26.10, 28.98) 63.41 (58.38–68.16) 60.49 (56.39–64.46) 72.65 (69.26–75.80)
Nicotine 15.86 (15.00, 16.76) 44.26 (39.93–48.69) 35.61 (31.79–39.62) 48.66 (44.65–52.69)
Cannabis 7.45 (6.79, 7.96) 23.65 (19.81–27.94) 18.59 (15.40–22.27) 23.66 (20.24–27.46)
Amphetamine 1.69 (1.46, 1.95) 5.28 (3.45–7.99) 5.74 (3.97–8.24) 7.09 (5.47–9.14)
Opiates 1.16 (1.00, 1.36) 3.23 (2.07–5.01) 4.05 (2.52–6.43) 6.73 (4.88–9.21)
Sedative 0.89 (0.78, 1.02) 1.92 (1.08–3.39) 3.08 (1.97–4.78) 4.72 (3.17–6.98)
Tranquilizer 0.84 (0.72, 0.97) 1.59 (0.89–2.85) 2.50 (1.50–4.15) 4.20 (2.75–6.37)
Inhalant/Solvent 0.25 (0.19, 0.32) 0.33 (0.10–1.09) 2.12 (1.23–3.63) 1.66 (0.91–3.01)
Cocaine 2.44 (2.23, 2.67) 6.18 (4.63–8.21) 6.44 (4.72–8.73) 9.99 (7.65–12.95)
Hallucinogen 1.43, (1.25, 1.63) 4.75 (3.27–6.84) 4.76 (3.15–7.15) 5.84 (4.32–7.86)
Heroin 0.18 (0.14, 0.24) 0.18 (0.05–0.60) 0.84 (0.32–2.18) 0.67 (0.30–1.47)
Psychotic disorder 0.77 (0.67, 0.89) 1.07 (0.50–2.32) 1.36 (0.72–2.54) 1.14 (0.40–3.23)
Cigarettes Smoked
Yes 41.74 (40.45, 43.03) 70.12 (66.24, 73.72) 75.17 (71.66, 78.37) 74.37 (71.05, 77.44)
No 58.26 (56.97, 59.54) 29.88 (26.28, 33.76) 24.83 (21.63, 28.34) 25.63 (22.56, 28.95)
Note: Boldface percentages are significantly different from those in the non-tobacco use group (p,0.05).
doi:10.1371/journal.pone.0113196.t002
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Table 4 shows multivariate analysis results by comparing exclusive snuff or
chewing tobacco use anddual use with respect to psychiatric disorders after
controlling for demographic covariates. Compared to the dual use of smokeless
tobacco, the likelihood of exclusive snuff use wasreduced by 35% and 52%,
respectively, for people with alcohol use disorder and schizoid personality
disorder. Opioid use disorder was not associated with the greater odds of dual use
of snuff and chewing tobacco versus exclusive use of either product. The odds of
chewing tobacco were reduced by 42% and 33%, respectively, for people with
antisocial personality disorder and alcohol use disorder. In contrast, panic
Table 3. Adjusted odds ratios (OR) and 95% confidence intervals for lifetime psychiatric disorders while controlling for sociodemographic characteristics and
quantity of cigarettes smoked.
Snuff Chewing tobacco Snuff and chewing tobacco
OR (95%CI) OR (95%CI) OR (95%CI)
Mood disorders
Major depression 1.00 (0.77, 1.30) 0.78 (0.58, 1.05) 1.06 (0.80, 1.41)
Dysthymia 0.96 (0.54, 1.71) 1.42 (0.93, 2.18) 1.18 (0.74, 1.88)
Mania/hypomania 1.00 (0.68, 1.47) 1.09 (0.77, 1.55) 0.90 (0.66, 1.22)
Anxiety disorders
Panic disorder 0.83 (0.45, 1.53) 1.53 (1.01, 2.30) 0.65 (0.37, 1.15)
Social phobia 1.19 (0.76, 1.86) 1.15 (0.72, 1.83) 0.72 (0.49, 1.05)
Specific phobia 1.03 (0.73, 1.45) 1.41 (1.04, 1.92) 0.87 (0.65, 1.17)
General Anxiety Disorder 0.78 (0.45, 1.34) 0.68 0.43, 1.09) 0.99 (0.56, 1.75)
Personality Disorder
Avoidant 1.10 (0.57, 2.11) 1.00 (0.51, 1.98) 1.01 (0.54, 1.89)
Depressive 0.66 (0.15, 2.92) 0.78 (0.19, 3.10) 1.40 (0.49, 4.00)
Obsessive-Compulsive 1.11 (0.77, 1.61) 1.10 (0.81, 1.50) 1.29 (0.97, 1.71)
Paranoid 1.37 (0.84, 2.24) 0.94 (0.59, 1.48) 1.12 (0.75, 1.67)
Schizoid 0.58 (0.33, 1.02) 0.87 (0.52, 1.47) 1.18 (0.77, 1.81)
Antisocial 1.23 (0.86, 1.77) 0.75 (0.52, 1.06) 1.18 (0.86, 1.61)
Histrionic 0.61 (0.30, 1.22) 1.27 (0.74, 2.18) 1.11 (0.72, 1.72)
Conduct disorder 0.78 (0.35, 1.75) 0.65 (0.30, 1.40) 1.05 (0.59, 1.89)
Substance Use Disorders
Alcohol 1.97 (1.59, 2.45) 2.01 (1.65, 2.44) 2.99 (2.46, 3.62)
Cannabis 1.44 (1.09, 1.90) 1.34 (0.99, 1.81) 1.12 (0.87, 1.46)
Amphetamine 1.41 (0.73, 2.71) 1.56 (0.89, 2.73) 1.29 (0.85, 1.98)
Opioid 1.08 (0.58, 2.02) 1.35 (0.65, 2.79) 1.81 (1.09, 3.03)
Sedative 0.83 (0.40, 1.72) 0.82 (0.41, 1.62) 1.41 (0.62, 2.11)
Tranquilizer 0.46 (0.21, 1.05) 0.55 (0.27, 1.12) 0.59 (0.29, 1.20)
Inhalant/Solvent 0.39 (0.12, 1.34) 3.33 (1.58, 7.04) 1.19 (0.49, 2.91)
Cocaine 0.76 (0.50, 1.18) 0.80 (0.46, 1.39) 1.10 (0.73, 1.67)
Hallucinogen 1.01 (0.61, 1.69) 1.06 (0.55, 2.04) 0.74 (0.45, 1.20)
Psychotic disorder 1.29 (0.52, 3.23) 1.19 (0.55, 2.58) 0.85 (0.20, 3.62)
Note: All odds ratios were adjusted for the demographic covariates, quantity of cigarette smoked and the rest psychiatric correlates presented in the table.
Boldface odds ratios are significantly significant (p,0.05).
doi:10.1371/journal.pone.0113196.t003
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disorder, specific phobia and inhalant or solvent use disorder were associated with
greater odds of exclusive chewing tobacco compared to dual use.
Discussions
We have yielded some new findings by including a broader range of psychiatric
correlates, using a lifetime diagnosis and specifying subtypes of smokeless tobacco
Table 4. Associations between lifetime psychiatric disorders and exclusive smokeless tobacco use status compared to dual use of snuff and chewing
tobacco while controlling for sociodemographic characteristics and quantity of cigarettes smoked.
Snuff Chewing tobacco
OR (95%CI) OR (95%CI)
Mood disorders
Major depression 0.98 (0.70–1.38) 0.77 (0.53–1.13)
Dysthymia 0.72 (0.38–1.33) 1.13 (0.62–2.05)
Mania/hypomania 1.24 (0.77–1.99) 1.29 (0.82–2.02)
Anxiety disorders
Panic disorder 1.13 (0.49–2.59) 2.24 (1.09–4.64)
Social phobia 1.57 (0.87–2.85) 1.73 (0.96–3.12)
Specific phobia 1.22 (0.76–1.95) 1.71 (1.15–2.53)
General Anxiety Disorder 0.79 (0.39–1.60) 0.61 (0.32–1.17)
Personality Disorder
Avoidant 1.27 (0.51–3.15) 0.92 (0.35–2.40)
Dependent 0.45 (0.06–3.46) 0.55 (012–2.53)
Obsessive-Compulsive 0.85 (0.53–1.37) 0.91 (0.61–1.34)
Paranoid 1.20 (0.65–2.21) 0.84 (0.45–1.59)
Schizoid 0.48 (0.25–0.94) 0.67 (0.33–1.38)
Antisocial 1.06 (0.69–1.63) 0.58 (0.38–0.90)
Histrionic 0.57 (0.24–1.35) 1.36 (0.67–2.74)
Conduct disorder 0.69 (0.26–1.85) 0.69 (0.28–1.72)
Substance Use Disorders
Alcohol 0.65 (0.49–0.86) 0.67 (0.51–0.89)
Quantity of cigarettes 1.01 (0.94–1.09) 1.01 (0.94–1.09)
Cannabis 1.23 (0.84–1.79) 1.18 (0.81–1.72)
Amphetamine 0.91 (0.46–1.82) 1.09 (0.60–1.99)
Opioid 0.50 (0.24–1.06) 0.66 (0.29–1.52)
Sedative 0.79 (0.27–2.38) 0.94 (0.34–2.56)
Tranquilizer 0.83 (0.26–2.63) 0.76 (0.29–2.00)
Inhalant/Solvent 0.38 (0.08–1.86) 3.16 (1.11–9.03)
Cocaine 0.66 (0.37–1.18) 0.73 (0.36–1.50)
Hallucinogen 1.65 (0.73–3.75) 1.60 (0.70–3.53)
Psychotic disorder 1.08 (0.30–3.93) 1.41 (0.46–4.30)
Note: All odds ratios were adjusted for the demographic covariates and the rest psychiatric correlates presented in the table. Boldface odds ratios are
significantly significant (p,0.05).
doi:10.1371/journal.pone.0113196.t004
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use. Unlike cigarette smoking, which is associated with a broad range of
psychiatric disorders, lifetime smokeless tobacco use is associated with a subset of
lifetime diagnoses of psychiatric disorders. The profile of lifetime psychiatric
correlates is different depending on the type of smokeless tobacco used. For
example, panic disorder and specific phobia were associated with a greater
likelihood of exclusive chewing tobacco in our study, consistent with a positive
association between smokeless tobacco use and specific phobia was reported
among people with nicotine dependence previously [10]. A positive association
between lifetime cannabis use disorder and lifetime exclusive snuff use was found
in this study, inconsistent with the previous study which concluded that smokeless
tobacco use was not associated with cannabis use disorder [11]. We demonstrated
a strong positive association between inhalant or solvent use disorder and
exclusive chewing tobacco, which had not been reported previously. Alcohol use
disorder is associated with all types of smokeless tobacco use. Furthermore,
compared to dual use of snuff and chewing tobacco, exclusive use of either type of
smokeless tobacco product is uniquely associated with different lifetime diagnoses
of psychiatric disorders.
The present study is different from the previous studies [10, 11] in several
important ways. First, in the previous studies, smokeless tobacco use was treated
as an independent variable and psychiatric disorders were dependent variables. In
the present study, smokeless tobacco use was treated as a dependent variable and
psychiatric disorders were independent variables. This analytical approach
facilitates detection of whether each psychiatric disorder is independently
associated with smokeless tobacco use. Second, unlike previous studies that
combined snuff use and chewing tobacco together and focused on comparisons
between smoked and smoked plus smokeless tobacco use, the present study
exclusively focused on smokeless tobacco use. As such, we were able to examine
the effect of specific types of smokeless tobacco use. Third, to maximize the
sample size of smokeless tobacco use, lifetime smokeless tobacco users were
included in the analysis. In contrast, Goodwin et al. [10] study included only past-
year smokeless tobacco users. Agrawal and Lynskey’s [11] study divided smokeless
tobacco users into exclusive smokeless tobacco users and smoke plus smokeless
tobacco use. As a result, the sample size of smokeless tobacco users is significantly
reduced. In the present study, it was recognized that many smokeless tobacco
users were also smokers. We controlled the smoking effects by including
quantities of cigarettes smoked as a covariate. Finally, the relation of smokeless
tobacco use with cannabis use and cannabis use disorder was the central focus in a
previous study [11], while the present study examined a broad spectrum of
psychiatric disorders in relation to each specific type of smokeless tobacco use.
Exclusive smokeless tobacco use has been linked to alcohol use disorder [11].
Our study extends the previous finding by demonstrating that alcohol use
disorder is associated with all types of smokeless tobacco use. Moreover, the
association between dual use and alcohol use disorder is much stronger than that
between exclusive use of either type of smokeless tobacco and alcohol use
disorder. This strong association cannot be explained by cigarette smoking,
Psychiatric Correlates of Snuff and Chewing Tobacco Use
PLOS ONE | DOI:10.1371/journal.pone.0113196 December 23, 2014 10 / 14
sociodemographics and other psychiatric disorders. The biological mechanism of
the association between smokeless tobacco use and alcohol use disorder is not
clear. Little research has elucidated the biological link between smokeless tobacco
and alcohol dependence. Alcohol dependence and cigarette smoking are
associated with low platelet monoamine oxidase (MAO) activity levels. Cigarette
smoking leads to the binding of an inhibitor contained in cigarette smoke to
platelet MAO-B at the catalytic site of MAO. However, a recent Swedish study
compared the MAO activity of three groups of tobacco use among alcohol
dependent subjects: non-tobacco users (n546), snuff users (n514), and cigarette
users (n533) [24]. The MAO activity levels were significantly lower in cigarette
smokers, but not in snuff users, compared to non-tobacco users. This finding
suggests that snuff use may not have an inhibitory effect on MAO activities among
alcohol dependence users. It is unknown if this phenomenon can be observed in
people without alcohol dependence. Low aldehyde dehydrogenase (ALDH)
activity is a marker of alcohol dependence. The mean whole blood ALDH activity
of the smokers was found to be reduced significantly in smokers, but not in snuff
users [25], even though cigarette smokers and snuff users had similar plasma
nicotine and cotinine levels. The investigators speculated that the reduced blood
ALDH activity in smokers was not caused by nicotine or any of its metabolites,
but more likely, by components formed during the combustion of tobacco. In
combination, these studies suggest that the biological mechanism underlying the
association between cigarette use and alcohol use disorder cannot be
automatically extrapolated to the relationship between smokeless tobacco use and
alcohol use disorder. More research is needed to uncover the underlying
mechanism.
The present study did not identify a significant relationship between possession
of any mood disorder and smokeless tobacco use, consistent with a previous
report in the USA[10], but inconsistent with a Finnish adolescent longitudinal
study that found that early onset depressive disorders predicted two times the risk
for smokeless tobacco use three years later [26]. These inconsistent findings could
be attributable to study design (i.e. longitudinal vs. cross-sectional), difference in
controlling for confounding effects, and different cultural factors that exist
between Finland and USA.
The finding of an association between inhalant/solvent use disorder and
exclusive chewing tobacco is quite novel. People who had a lifetime diagnosis of
inhalant or solvent use disorder are three times more likely to chew tobacco than
those without inhalant/solvent use disorder. Previous studies have shown that
inhalant abuse is usually initiated during preadolescence [27] and chewing
tobacco often begins in adulthood [28]. Therefore, people with a history of
inhalant abuse may be at high risk for chewing tobacco at some point in their life.
Our novel finding may inform the primary prevention effort for chewing tobacco
use. Future research that uses a prospective design is needed to confirm our
hypothesized pathway.
Dual use of snuff and chewing tobacco versus exclusive use of one of the two
types of smokeless tobacco has not been investigated previously. The present study
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found that both panic disorder and specific phobia were associated with greater
odds of exclusive chewing tobacco rather than exclusive snuff use and dual use of
both smokeless tobacco products. These findings suggest that chewing tobacco is
specifically linked to panic disorder and specific phobia. In addition, schizoid and
antisocial personality disorder is less likely to be associated with exclusive use of
snuff and chewing tobacco, respectively, than dual use. These results may inform
secondary prevention of smokeless tobacco use. Depending on different types of
smokeless tobacco used, one or two particular psychiatric comorbidities should be
taken into account during the treatment.
The present study’s results should be interpreted within the context of several
limitations. Because present findings were derived from a cross-sectional study,
causal relations between smokeless tobacco and psychiatric disorders cannot be
determined. Lifetime diagnoses of psychiatric disorders and lifetime smokeless
tobacco use used in this study may obscure some true relationships between
smokeless tobacco use and psychiatric disorders. It is also possible that the
observed associations are due to a common cause that was not measured in this
study. Future studies employing prospective design are needed to unravel the
mechanism that underlies the identified associations. The present study’s findings
were derived based on interviews with adults 18 years or older included in the
NESARC dataset and the vast majority of smokeless users were men. Thus, results
may not apply equally well to the adolescent population. Future research in that
special population is needed to confirm current findings. Finally, we could not
examine the subtypes of smokeless tobacco use in relation to heroin use disorder
due to a small proportion of smokeless tobacco users who met the lifetime DSM-
IV diagnostic criteria for heroin use disorder.
Despite those limitations, this is the first epidemiologic study of its kind to
systematically examine the associations between each specific type of lifetime
smokeless tobacco use and lifetime diagnoses of psychiatric disorders. As such,
these findings provide new insights into the link of psychiatric disorders with
snuff use and chewing tobacco. These links are understudied yet given the public
health significance of smokeless tobacco product and their health consequences.
Thus, elucidating the link between psychiatric and behavioral health factors is
important. These results can guide treatment efforts on smokeless tobacco by
targeting the treatment for alcohol use disorder among all smokeless tobacco
users, the treatment for panic disorder, specific phobia, and inhalant use disorder
among exclusive chewing tobacco users, as well as the treatment for cannabis use
disorder among exclusive snuff users. It is helpful to realize that persons who use
both snuff and chewing tobacco are different from exclusive users of snuff or
chewing tobacco regarding their comorbid antisocial and schizoid personality
disorders, respectively.
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